Trial reportJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2014
Pamidronate attenuates muscle loss after pediatric burn injury.
Trial report in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04742010 (Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- Effect of Zoledronic Acid on Skeletal Muscle After Bariatric Surgery: A Secondary Analysis From a Randomized Controlled Trial.Obesity (Silver Spring, Md.) · 2026Trial
- Trial
- The effect of burn on serum concentrations of sclerostin and FGF23.Burns : journal of the International Society for Burn Injuries · 2015Trial
- Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026Review
- Association between vitamin D status and circulating myokines (irisin, myostatin, and myonectin) in children: A cross-sectional study.PloS one · 2026Article
- Metabolic and Hormonal Changes in Pediatric Burn Patients: Mechanisms, Evidence, and Care Strategies.European burn journal · 2025Review
- Molecular mechanisms of post-burn muscle wasting and the therapeutic potential of physical exercise.Journal of cachexia, sarcopenia and muscle · 2023Review
- Effects of antiresorptive agents on body composition: a case-control retrospective study.Reumatologia · 2023Article
- Current understanding of the chronic stress response to burn injury from human studies.Burns & trauma · 2023Review
- The Role of Vitamin E in Thermal Burn Injuries, Infection, and Sepsis: A Review.Journal of burn care & research : official publication of the American Burn Association · 2022Review
- Article
- RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Transforming Growth Factor-Beta in Skeletal Muscle Wasting.International journal of molecular sciences · 2022Review
- Editorial: Osteoporosis and the Role of Muscle.Frontiers in endocrinology · 2022Article
- Role of myokines and osteokines in cancer cachexia.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Severe injury-induced osteoporosis and skeletal muscle mineralization: Are these related complications?Bone reports · 2021Article
- The Role of Bone in Muscle Wasting.International journal of molecular sciences · 2020Review
- Pharmacologic Treatments to Preserve Bone and Muscle Mass in Osteosarcopenia.Current osteoporosis reports · 2020Review
- The role of the musculoskeletal system in post-burn hypermetabolism.Metabolism: clinical and experimental · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Children who are burned >40% total body surface area lose significant quantities of both bone and muscle mass because of acute bone resorption, inflammation, and endogenous glucocorticoid production, which result in negative nitrogen balance. Because administration of the bisphosphonate pamidronate within 10 days of the burn injury completely prevents the bone loss, we asked whether muscle protein balance was altered by the preservation of bone. We reviewed the results from 17 burned pediatric subjects previously enrolled in a double-blind randomized controlled study of pamidronate in the prevention of post-burn bone loss and who were concurrently evaluated for muscle protein synthesis and breakdown by stable isotope infusion studies during the acute hospitalization. We found a significantly lower fractional protein synthesis rate (FSR) in the pamidronate group and a correspondingly lower rate of appearance of the amino acid tracer in venous blood, suggesting lower muscle protein turnover. Moreover, net protein balance (synthesis minus breakdown) was positive in the subjects receiving pamidronate and negative in those receiving placebo. Muscle fiber diameter was significantly greater in the pamidronate subjects and leg strength at 9 months post-burn was not different between subjects who received pamidronate and normal physically fit age-matched children studied in our lab. Leg strength in burned subjects who served as controls tended to be weaker, although not significantly so. If substantiated by a larger study, these results suggest that bone may have a paracrine mechanism to preserve muscle and this finding may have implications for the treatment of sarcopenia in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.